GeneDx (WGS) CFO Kevin Feeley Sells Shares to Cover Taxes

What Happened Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had 2,462 restricted stock units (RSUs convert/vested into shares) settle on September 9, 2026 and sold 1,285 of those shares in an open-market "sell to cover" transaction for a weighted average price of $84.22, generating proceeds of $108,220. The RSUs were converted/settled for no cash consideration (each RSU converts to one share on settlement).

Key Details

• Transaction date: September 9, 2026.
• Sales: 1,285 shares sold (open-market) at a weighted average price $84.22; proceeds $108,220. Reported sale prices ranged $84.08–$84.22. (Footnote F3.)
• Settlement/conversion: 2,462 RSUs converted/settled into shares at $0.00 (reported as derivative exercise/conversion). (Footnote F1.)
• Purpose: Sale executed to satisfy tax withholding obligations relating to RSU vesting — a non-discretionary "sell to cover" (Footnote F2).
• Holdings after transaction: 41,476 shares of Class A common stock beneficially owned, plus RSUs representing rights to up to 78,864 additional shares and options to purchase up to 25,906 shares (these vest per their terms). (Footnote F4.)
• Vesting detail: The RSU award vests 6.25% quarterly (first tranche vested March 9, 2023); RSUs have no expiration — they either vest or are cancelled per schedule. (Footnote F5.)
• Filing: Form 4 filed September 11, 2026 for a September 9 transaction (appears timely within the 2-business-day Form 4 window).

Context

• This was not an open-market investment buy — it was a routine tax-withholding sale tied to RSU settlement. Such "sell to cover" transactions are common after equity awards vest and do not necessarily reflect a change in the insider's view of the company.
• Derivative/RSU explanation: RSUs are contingent rights that convert to shares upon vesting for no cash payment; the reported exercise/conversion lines reflect that settlement.